Word Search (Top 10 - by date)

Gilead Sciences Announces First Quarter 2016 Financial Results
Gilead Sciences (April 28, 2016)
Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results
Gilead Sciences (February 02, 2016)
Gilead Sciences Announces Third Quarter 2015 Financial Results
Gilead Sciences (October 27, 2015)
Gilead Sciences Announces Second Quarter 2015 Financial Results
Gilead Sciences (July 28, 2015)

Displaying 10 out of a possible 231 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Macugen
Generic Name:   pegaptanib sodium
Therapeutic Subcategory:     Eye/Ophthalmic preparations

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Macugen1 69


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Macugen

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now